News Agency
The Times

VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism

  • Written by PR Newswire
  • 77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the primary multi-component endpoint compared to 0.0% for placebo (p <0.0001)
  •  Palopegteriparatide was generally safe and well-tolerated, with no discontinuations related to study drug.

SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- VISEN Pharmaceuticals, an...

Read more: VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide...

How to Choose a Local SEO Agency That Can Generate Real Enquiries, Not Just Rankings

A local SEO proposal may promise improved Google Maps visibility, extra keywords, and monthly reports. Those can be useful, but they do not automatically mean the business will receive more calls from suitable customers. Before committing to a contract, owners... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion